Eisai gets longer to argue Cancer Drugs Fund rulingEisai’s breast cancer treatment Halaven will remain on the Cancer Drugs Fund after the firm’s appeal was granted. Share XEisai gets longer to argue Cancer Drugs Fund rulinghttps://pharmaphorum.com/news/eisai-wins-appeal-on-cancer-drugs-fund-ruling/
First patients diagnosed in 100,000 Genomes ProjectThe UK’s National Health Service (NHS) has taken its first steps towards providing personalised care based on genomic Share XFirst patients diagnosed in 100,000 Genomes Projecthttps://pharmaphorum.com/news/first-patients-diagnosed-in-100-000-genomes-project/
SMC okays Novartis’ Jakavi as competition loomsNovartis’ Jakavi will be available to patients in Scotland with the bone marrow cancer myelofibrosis after a positive Share XSMC okays Novartis’ Jakavi as competition loomshttps://pharmaphorum.com/news/smc-okays-novartis-jakavi-as-competition-looms/
The Apple Watch is finally hereAfter all the hype and expectation, Apple’s smartwatch has finally been shown to the public and will go Share XThe Apple Watch is finally herehttps://pharmaphorum.com/news/the-apple-watch-is-finally-here/
Sandoz bags first-ever biosimilar approval in USNovartis generics subsidiary Sandoz made history ahead of the weekend after getting approval in the US for Zarxio, Share XSandoz bags first-ever biosimilar approval in UShttps://pharmaphorum.com/news/sandoz-bags-first-ever-biosimilar-approval-in-us/
Recruitment problems scupper Bayer liver metastasis trialBayer has been forced to abandon a Phase III trial of its Stivarga drug in liver metastases after Share XRecruitment problems scupper Bayer liver metastasis trialhttps://pharmaphorum.com/news/recruitment-problems-scupper-bayer-liver-metastasis-trial/
Stem cell and gene therapy combination to target lung cancerA pioneering new lung cancer therapy combining cell therapy and gene therapy is to be tested on patients Share XStem cell and gene therapy combination to target lung cancerhttps://pharmaphorum.com/news/stem-cell-and-gene-therapy-combination-to-target-lung-cancer/
Summit Therapeutics to raise funds for Duchenne and C diff drugsUK biotech firm Summit Therapeutics is preparing a US share offer to raise funding for its research programmes. Share XSummit Therapeutics to raise funds for Duchenne and C diff drugshttps://pharmaphorum.com/news/summit-therapeutics-to-raise-funds-for-duchenne-and-c-diff-drugs/
AbbVie swoops for Pharmacyclics in $21bn takeoverJohnson & Johnson has missed out on acquiring its marketing partner Pharmacyclics after AbbVie snatched the company from Share XAbbVie swoops for Pharmacyclics in $21bn takeoverhttps://pharmaphorum.com/news/abbvie-swoops-for-pharmacyclics-in-21bn-takeover/
